Coronavirus Notebook: EU Joins COVAX, Sanofi/GSK Vaccine Moves To Phase I/II
Executive Summary
Convalescent plasma has taken another battering as a potential treatment for coronavirus patients, after a UK drug safety body agreed with a US expert panel that there was not yet enough evidence to recommend its use in COVID-19 patients.
You may also be interested in...
Russia To Roll Out COVID-19 Vaccine Based On Phase II Data
Early data suggests double adenovirus candidate has promise – but Russia plans key worker vaccinations ahead of pivotal trial.
Coronavirus Update: Sanofi And GSK’s ‘Tortoise’ Joins Hares In Vaccine Race
Initial results from the study are expected in early December 2020, which would allow the start of a Phase III trial before the end of the year.
Coronavirus Notebook: UK Reveals Plans For Pre-Approval Use Of COVID-19 Vaccine
The UK government is proposing to take the "very unusual step" of making COVID-19 vaccines available before they are licensed. The international COVAX initiative is now supporting nine vaccines, and the EU and AstraZeneca have firmed up a vaccine purchase agreement.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: